Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Orano, Sanofi
Sanofi and Orano Med link for radioligand therapy development
Sanofi and Orano Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation radioligand therapies (RLTs) for rare cancers. The companies plan to invest in a new entity,
Sanofi invests €300m in Orano Med's lead-based radioligands
The transaction builds on a three-way partnership between Sanofi, Orano Med, and RadioMedix – signed in September with a €100 million upfront payment – to develop a radioligand therapy (RLT) for rare neuroendocrine tumours (NETs) called AlphaMedix (212Pb-dotamtate).
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies
Sanofi SNY announced that it has entered into an agreement with France-based cancer biotech Orano Med to jointly develop next-generation radioligand therapies for treating rare cancers.Radioligand therapy is a type of precision cancer treatment that combines a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle).
Sanofi returns to Orano with €300M for radioligand 'pioneer' project
Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, Sanofi has returned with 300 million euros ($326 million) to set up a more | The new entity,
Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
Sanofi and Orano join forces to develop next-generation radioligand medicinesParis, October 17, 2024. Sanofi and Orano Med, a subsidiary of the
Sanofi and Orano Med partner on next-gen radioligand therapies
Sanofi has partnered with Orano Med, a subsidiary of Orano Group, to develop radioligand therapies for rare cancers. Sanofi will invest €300 million for a 16% stake in the venture. The collaboration focuses on using lead-212 isotopes to target difficult-to-treat cancers.
Sanofi & Orano join forces to accelerate the development of develop next-generation radioligand medicines
Sanofi & Orano join forces to accelerate the development of develop next-generation radioligand medicines: Paris Friday, October 18, 2024, 10:00 Hrs [IST] Sanofi and Orano Med, a
PMLiVE
4d
Sanofi and Orano Med partner to advance radioligand therapies for rare cancers
Sanofi
and
Orano
Med
have announced a new partnership aimed at accelerating the development of next-generation ...
BioSpace
4d
Sanofi Inks $326M Radiopharma Deal With Orano
Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the ...
MedCity News
4d
Sanofi Puts Up €300M in New Targeted Radiation Cancer Therapy Pact With Orano
The new entity will operate under the brand of
Orano
Med
, a subsidiary of
Orano
Group.
Sanofi
already has a relationship with
Orano
Med
. Last month, the Paris-based pharmaceutical giant ...
4d
Sanofi, expanding in radiopharma, strikes a joint venture deal
The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback